The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).
 
Ken Kondo
No Relationships to Disclose
 
Sotaro Sadahiro
No Relationships to Disclose
 
Kazuhiro Sakamoto
No Relationships to Disclose
 
Takashi Tsuchiya
No Relationships to Disclose
 
Takao Takahashi
No Relationships to Disclose
 
Hiroki Ohge
No Relationships to Disclose
 
Toshihiko Sato
No Relationships to Disclose
 
Yukata Ogata
No Relationships to Disclose
 
Hideo Baba
Honoraria - Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Johnson & Johnson K.K. (Inst); Lilly Japan (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Michio Itabashi
No Relationships to Disclose
 
Masataka Ikeda
Speakers' Bureau - Taiho Pharmaceutical
 
Madoka Hamada
No Relationships to Disclose
 
Kiyoshi Maeda
No Relationships to Disclose
 
Hiroyuki Masuko
No Relationships to Disclose
 
Keiichi Takahashi
No Relationships to Disclose
 
Junichi Sakamoto
No Relationships to Disclose
 
Mitsuo Kusano
No Relationships to Disclose
 
Ichinosuke Hyodo
Honoraria - Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Asahi Kasei; Chugai Pharma; Daiichi Sankyo Co.,Ltd.; Merck; Taiho Pharmaceutical
 
Masataka Taguri
No Relationships to Disclose
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Kyowa Kirin Co., Ltd.; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Eisai (Inst)